Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marwan Fakih

Showing results (151-160 of 200) with videos related to

Pageof 20
Sort By:
Clinical Colorectal Cancer|April 23, 2024
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and EEric X Chen, Petr Kavan, Mustapha Tehfe, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2005
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignanciesRamesh K Ramanathan, Sakkaraiappan Ramalingam, Merrill J Egorin, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal of Oncology Practice|September 15, 2016
Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With CancerArti Hurria, Chie Akiba, Jerome Kim, et al.
Cancer|January 17, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3Jeffrey S Ross, Marwan Fakih, Siraj M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 StudyJonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE StudyCaiming Xu, Alessandro Mannucci, Francis Esposito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumorsWilliam C Zamboni, Laura L Jung, Merrill J Egorin, et al.
Nature Communications|June 7, 2023
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerTakayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, et al.
Pageof 20

Showing results (151-160 of 200) with videos related to

Sort By:
Pageof 20
Clinical Colorectal Cancer|April 23, 2024
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and EEric X Chen, Petr Kavan, Mustapha Tehfe, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2005
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignanciesRamesh K Ramanathan, Sakkaraiappan Ramalingam, Merrill J Egorin, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal of Oncology Practice|September 15, 2016
Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With CancerArti Hurria, Chie Akiba, Jerome Kim, et al.
Cancer|January 17, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3Jeffrey S Ross, Marwan Fakih, Siraj M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 StudyJonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE StudyCaiming Xu, Alessandro Mannucci, Francis Esposito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumorsWilliam C Zamboni, Laura L Jung, Merrill J Egorin, et al.
Nature Communications|June 7, 2023
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerTakayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, et al.
Pageof 20